| Hypertensive disease
Benicar vs Katerzia
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Benicar vs Katerzia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKaterzia has a higher rate of injection site reactions vs Benicar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Katerzia but not Benicar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Benicar
Katerzia
At A Glance
Oral
Daily
Angiotensin II receptor antagonist
Oral
Daily
Calcium channel blocker
Indications
- Hypertensive disease
- Hypertensive disease
- Stable angina
- Angina Pectoris, Variant
- Coronary Artery Disease
Dosing
Hypertensive disease (Adults) Starting dose 20 mg once daily; may increase to 40 mg once daily after 2 weeks if further blood pressure reduction needed; oral.
Hypertensive disease (Pediatric, 6 years and older) 10 mg once daily for patients weighing 20 to <35 kg; 20 mg once daily for patients weighing >=35 kg; oral tablet or extemporaneous suspension.
Hypertensive disease (adults) 5 mg orally once daily (max 10 mg); start 2.5 mg in small, fragile, elderly patients, or those with hepatic insufficiency.
Hypertensive disease (pediatric, ages 6-17) 2.5-5 mg orally once daily; doses >5 mg have not been studied in pediatric patients.
Stable angina, Angina Pectoris, Variant 5-10 mg orally once daily; lower dose suggested in elderly and patients with hepatic insufficiency; most patients require 10 mg.
Coronary Artery Disease 5-10 mg orally once daily; majority of patients required 10 mg in clinical studies.
Contraindications
- Co-administration of aliskiren in patients with diabetes
- Known sensitivity to amlodipine
Adverse Reactions
Most common (>1%) Dizziness
Postmarketing Asthenia, angioedema, anaphylactic reactions, vomiting, sprue-like enteropathy, hyperkalemia, rhabdomyolysis, acute renal failure, increased blood creatinine levels, alopecia, pruritus, urticaria
Most common (>1%) edema, dizziness, flushing, palpitation, fatigue, nausea, abdominal pain, somnolence
Postmarketing gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder
Pharmacology
Olmesartan medoxomil is a selective AT1 subtype angiotensin II receptor antagonist that blocks vasoconstrictor effects of angiotensin II by selectively blocking its binding to the AT1 receptor in vascular smooth muscle, acting independently of angiotensin II synthesis pathways.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation, reduction in peripheral vascular resistance, and reduction in blood pressure.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Benicar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (1/12)
Katerzia
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (8/12)
UnitedHealthcare
Benicar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Katerzia
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Benicar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Katerzia
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Benicar.
No savings programs available for Katerzia.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BenicarView full Benicar profile
KaterziaView full Katerzia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.